Effects of HIV co-infection and chemotherapy on the urinary levels of nitric oxide metabolites in patients with pulmonary tuberculosis

Scandinavian Journal of Infectious Diseases

Volumn 31, Issue 2, 1999, Pages 123-126

  Schön, Thomas ^c   Gebre, Negussie ^a   Sundqvist, Tommy ^c   Aderaye, Getachew ^b   Britton, Sven ^a  

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; NITRATE; NITRIC OXIDE; NITRITE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; ETHIOPIA; FEMALE; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MACROPHAGE; MALE; METABOLITE; MYCOBACTERIUM TUBERCULOSIS; URINE LEVEL;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NITRATES; NITRIC OXIDE; NITRITES; TUBERCULOSIS, PULMONARY;

EID: 0032867991     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655499750006137     Document Type: Article

References (34)

1. Kochi A. The global situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1-6.
2. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175: 1111-22.
3. Chan J, Tanaka K, Carrol D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995; 63: 736-40.
4. Wei Xiao-qing, Charles IG, Smith A, Ure J, Feng Gui-jie, Huang Fang-ping, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-11.
5. Xie Qiao-wen, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 225-8.
6. Adams LB, Franzblau SG, Vavrin Z, Hibbs Jr JB, Krahenbuhl JL. L-arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J Immunol 1991; 147: 1642-6.
7. Khare S, Bhutani LK, Rao DN. Release of reactive nitrogen intermediates from the peripheral blood-derived monocytes/macrophages of leprosy patients stimulated in vitro by tuftsin. Leprosy Review 1997; 68: 16-24.
8. Vouldoukis I, Riveros-Moreno V, Dugas B, Ouaaz F, Becherel P, Debre P, et al. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the FcεRII/CD 23 surface antigen. Proc Natl Acad Sci 1995; 92: 7804-8.
9. Stenger S, Thüring H, Röllinghoff M, Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 1994; 180: 783-93.
10. Granger DL, Hibbs Jr JB. High-output nitric oxide: weapon against infection? Trend Microbiol 1996; 4: 46-7.
11. Denis M. NO or no NO? J Leukoc Biol 1994; 55: 682-4.
12. Schoedon G, Schneemann M, Walter R, Blau N, Hofer S, Schaffner A. Nitric oxide and infection: Another view. Clin Infect Dis 1995; 21 Suppl 2: S152-7.
13. Liang Yan R, Vandivier RW, Suffredini AF, Danner RL. Human polymorphnuclear leukocytes lack detectable nitric oxide synthase activity. J Immunol 1994; 153: 1825-34.
14. St Clair EW, Wilkinson WE, Lang T, Sanders L, Misukonis MA, Gilkeson GS, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996; 184: 1173-8.
15. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996; 184: 557-67.
16. Wheeler MA, Smith SD, García-Cardena G, Nathan CF, Weiss RM, Sessa WC. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 1997; 99: 110-6.
17. Nicholson S, Bonecini-Almeida M, Lapa e Silva JR, Nathan C, Xie Qiao-wen, Mumford R, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996; 183: 2293-302.
18. Änggård E. Nitric oxide: mediator, murderer and medicine. Lancet 1994; 343: 1199-206.
19. Green LC, De Luzuriaga KR, Wagner DA, Rand W, Istfan N, Young VR, et al. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981; 84: 6369-73.
20. Granger DL, Hibbs JB, Broadnax LM. Urinary nitrate excretion in relation to murine macrophage activation. J Immunol 1991; 146: 1294-302.
21. Dykhuizen RS, Masson J, McKnight G, Mowat ANG, Smith CC, Smith LM, et al. Plasma nitrate concentration in infective gastroenteritis and inflammatory bowel disease. Gut 1996; 39: 393-5.
22. Sundqvist T, Laurin P, Fälth-Magnusson K, Magnusson K-E, Stenhammar L. Significantly increased levels of nitric oxide products in urine of children with celiac disease. JPGN 1998; 27: 196-8.
23. Schön T, Gebre N, Sundqvist T, H/Mariam HS, Engeda T, Britton S. Increased levels of nitric oxide metabolites in urine from leprosy patients in reversal reaction. Lepr Rev 1999. In press.
24. Giliam MB, Sherman MP, Griscavage JM, Ignarro LJ. A spectrophotometric assay for Nitrate Using NADPH oxidation by Aspergillus nitrate reductase. Anal Biochem 1993; 212: 259-65.
25. Ellis G, Adatia I, Yazdanpanah M, Makela SK. Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin Biochem 1998; 31: 195-220.
26. Leone AM, Francis PL, Rhodes P, Moncada S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem Biophys Res Commun 1994; 200: 951-7.
27. Rhodes P, Leone AM, Francis PL, Struthers AD, Moncada S, Rhodes PM. The L-arginine: nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1994; 209: 590-6.
28. Demissie A, Ravn P, et al. T-cell recognition of extracellular mycobacterial antigens by tuberculosis patients and their household contacts. Infect Immun 1999. In press.
29. Garay, SM. Tuberculosis and the human immunodeficiency virus infection. In: Rom WN, Garay SM. Tuberculosis. New York: Little, Brown and Co., 1996: 443-65.
30. Bukrinsky MI, Nottet HSLM, Schmidtmayerova H, Dubroysky L, Flanagan CR, Mullins ME, et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: Implications for HIV-associated neurological disease. J Exp Med 1995; 181: 735-44.
31. Groeneveld PHP, Kroon FP, Nibbering PH, Bruisten SM, van Sweiten P, van Furth R. Increased production of nitric oxide correlates with viral load and activation of mononuclear phagocytes in HIV-infected patients. Scand J Infect Dis 1996; 28: 341-5.
32. Barnes P, Chan LS, Wong SF. The course of fever following treatment of tuberculosis. Tubercle 1987; 68: 255-60.
33. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent effector mechanism in murine macrophages. Eur J Immunol 1988; 18: 1587-92.
34. Ellner JJ. The immune response in human tuberculosis: implications for tuberculosis control. J Inf Dis 1997; 176: 1351-9.